Clinical Trials Logo

Major Depressive Disorder (MDD) clinical trials

View clinical trials related to Major Depressive Disorder (MDD).

Filter by:

NCT ID: NCT06044818 Recruiting - Clinical trials for Major Depressive Disorder (MDD)

Validation of Accexible as a Tool for Screening and Monitoring Depression.

Start date: January 22, 2024
Phase:
Study type: Observational

Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating Accexible as a tool for Screening and Monitoring Depression.

NCT ID: NCT05966532 Recruiting - Clinical trials for Major Depressive Disorder (MDD)

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

ENSURE
Start date: December 11, 2023
Phase:
Study type: Observational

This is a cross-sectional pilot study designed to establish hot and cold cognitive functions and underlying neurocircuitry in older adults with MDD. The investigators will study 60 participants aged 21-80 years old with MDD. All participants will undergo clinical and neurocognitive assessment, and Magnetoencephalography (MEG)/Magnetic resonance imaging (MRI) procedures at one time point. The investigators will also enroll 60 demographically matched comparable, never-depressed healthy participants (controls) to establish cognitive benchmarks. Healthy controls will complete clinical and neurocognitive measures at one time point. To attain a balanced sample of adults across the lifespan, the investigators will enroll participants such that each age epoch (e.g., 21-30, 31-40, etc.) has a total of ten subjects (n=10) in both the healthy control cohort and depressed cohort.

NCT ID: NCT05938179 Not yet recruiting - Clinical trials for Major Depressive Disorder (MDD)

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of continuous oral administration of HS-10353 in Chinese adults with depression.HS-10353 is a new generation of GABAA receptor isomeric modulator developed by our company, which can correct the dysfunction of GABAA receptor function and restore the balance between GABA receptor and NMDA receptor. Oral administration of HS-10353 at night for 14 days is expected to reduce clinical symptoms in patients with depression. As an oral preparation of allopregnenolone analogitics, it has good bioavailability, rapid onset and high safety, and has broad clinical application prospects, which is expected to better meet the treatment needs of clinical depression in China in the future.

NCT ID: NCT05762458 Not yet recruiting - Clinical trials for Major Depressive Disorder (MDD)

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Ammoxetine
Start date: February 28, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

NCT ID: NCT05541302 Completed - Clinical trials for Major Depressive Disorder (MDD)

Retrospective TMS Therapy for Adults With MDD

Start date: November 1, 2008
Phase:
Study type: Observational

Examine change in the magnitude of antidepressant effects as a function of number of TMS sessions and to determine whether extended treatment courses, beyond 30 and beyond 36 TMS sessions, result in improved efficacy.

NCT ID: NCT05504486 Withdrawn - Clinical trials for Major Depressive Disorder (MDD)

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Start date: August 29, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

NCT ID: NCT05417087 Completed - Clinical trials for Major Depressive Disorder (MDD)

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Start date: June 27, 2022
Phase: Phase 1
Study type: Interventional

An open label, randomized, three-period, three-treatment [Treatment A (test product administered without water), Treatment B (test product administered with water) and Treatment C (Reference product administered with water)], six-sequence, crossover, balanced, single dose oral bioequivalence study.

NCT ID: NCT05416957 Completed - Clinical trials for Major Depressive Disorder (MDD)

Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Start date: September 18, 2022
Phase: Phase 1
Study type: Interventional

An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence, crossover, balanced, single dose oral food effect bioavailability study.

NCT ID: NCT05018013 Recruiting - Clinical trials for Major Depressive Disorder (MDD)

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Start date: August 21, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

NCT ID: NCT04853407 Completed - Clinical trials for Major Depressive Disorder (MDD)

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Start date: December 5, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS score, as compared to placebo (no medicine) in participants with Major Depressive Disorder (MDD)